Literature DB >> 11679565

Emergence of extremely high penicillin and cefotaxime resistance and high-level levofloxacin resistance in clinical isolates of Streptococcus pneumoniae in Hungary.

K Glatz1, D Szabó, G Szabó, D Boriszova, F Rozgonyi.   

Abstract

Oxacillin disc diffusion tests revealed that 36.7% of 327 Hungarian Streptococcus pneumoniae strains from clinical specimens were not penicillin susceptible. Determination of the MICs of penicillin, cefotaxime and levofloxacin for these strains by Etest confirmed that 30 (9.2%), 19 (5.8%) and four to 11 (1.2-3.4%) were fully penicillin-, cefotaxime- and levofloxacin-resistant, respectively. Most had extremely high MICs. Lower respiratory tract strains were more resistant than those from the upper respiratory tract. Levofloxacin-resistant strains were either penicillin intermediate or resistant, but their MICs did not correlate strongly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679565     DOI: 10.1093/jac/48.5.731

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia.

Authors:  Glenn A Pankuch; Bülent Bozdogan; Kensuke Nagai; Arjana Tambić-Andrasević; Slavko Schoenwald; Tera Tambić; Smilja Kalenić; Sanja Plesko; Nastja K Tepes; Zdenka Kotarski; Marina Payerl-Pal; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 2.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones.

Authors:  J Mensa; A Trilla
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

4.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.